FAQ

Anyone who has ever purchased pharmaceuticals at a pharmacy in Spain, France, Greece, or Italy and was pleased with the low prices knows that many branded pharmaceuticals are far less costly in other European countries than here in Germany, because as far as pharmaceutical prices are concerned, Germany ranks at the top within Europe. As an importer of pharmaceuticals, EurimPharm takes advantage of the price gap with other EU countries and offers many well-known branded pharmaceuticals at a much better price in Germany. Dispensing cost-effective import pharmaceuticals is required both by law as well as by health insurance providers to ensure lower prices and thus cost reductions for pharmaceuticals.

Imported pharmaceuticals change neither sales nor the associated production quantity of pharmaceuticals of the respective pharmaceutical companies. Imported pharmaceuticals pose no threat to German jobs.
On the contrary, pharmaceutical importers such as EurimPharm have created more than 3,000 jobs in Germany. The impact on the German labour market is therefore positive.

The legislature has recognized the opportunity for savings without compromising quality in patient care and requires pharmacies to dispense imported pharmaceuticals. Statutory health insurance providers have also contractually obligated pharmacies to operate accordingly.

Due to different rules for labeling of pharmaceutical products in the various EU countries as well as different packaging designs, the packaging of pharmaceuticals may appear different. However, EurimPharm is under obligation to adapt pharmaceuticals to German provisions, which the company adheres to by means of labels or new outer packaging. Regardless of a visual difference in packaging from the German product, you can still be sure that they always contain the same original branded pharmaceutical product in original quality.

Although EurimPharm offers over 1,800 preparations and packaging versions, not every branded pharmaceutical product has a more cost-effective imported version. This is due in part to EurimPharm's focus on products that are subject to patent protection and for which no inexpensive alternatives containing the same active ingredient (generics) exist on the market. Please ask your physician or pharmacist whether the desired or prescribed medicine is available as an import pharmaceutical by EurimPharm.

EurimPharm import pharmaceuticals offer savings of up to 30 percent compared to the same German preparations. These savings will benefit you directly or indirectly via your health insurance provider. If the cost-effective imported pharmaceuticals amount to between €50 and €100, your co-payment in the pharmacy is likewise reduced.

According to the literature mentioned below MR-examinations in a strength of up to 3.0 Tesla in women who have a copper intrauterine device for contraception (IUD) in place, does not influence neither the results of the MR-examination nor the functional efficacy of the IUD.
Testing conducted to determine MRI issues for the copper IUDs indicated that these objects are safe for patients in the MR environment using MR systems operating at 3.0 Tesla or less. This includes all Copper IUDs.
An artifact may be seen for the metallic component of the IUD; however, the extent of this artifact is relatively small because of the low magnetic susceptibility of copper.

Lit.: Samuel A. Pasquale et al. Lack of interaction between magnetic resonance imaging and the copper-T380A IUD. Contraception, 1997, Vol. 55, pp. 169-173.
T. Hess et al. Safety of intrauterine contraceptive devices during MR imaging. European Radiology, 1996, Vol. 6, pp. 66-68.
Correia L, et al., Magnetic resonance imaging and gynecological devices. Contraception, 2012, Vol. 85, pp. 538-43.
Mark AS, Hricak. Intrauterine contraceptive devices: MR imaging. Radiology 1987, Vol.162, pp. 311-314.
Kido A, et al. Intrauterine devices and uterine peristalsis: evaluation with MRI. Magnetic Resonance Imaging, 2008, Vol. 26, pp. 54-58.
V. Berger et al. Magnetic field interactions of copper-containing intrauterine devices in 3.0-tesla magnetic resonance imaging: in vivo study. Korean J Radiol 2013, Vol. 14, pp. 416-422.
M. Zieman et al. Copper T 380A IUD and magnetic resonance imaging. Contraception 2007, Vol. 75, pp. 93-95.

EurimPharm IUDs may not be used in the instance of:

• Malignant diseases of the genital tract
• Vaginal bleeding
• Pregnancy
• Past history of ectopic pregnancy or predisposing factors
• Infections of the genital tract
• Sexually transmitted diseases within the last 12 months
• Abortion with infection within the last three months
• Pelvic inflammatory disease
• Uterine malformations (congenital or acquired)
• Allergy to copper

Past experience indicates that, in general, impairment of the contraceptive efficacy of EurimPharm IUDs by other pharmaceuticals is highly unlikely. However, published reports appear to show diminished efficacy in case of long-term use of non-steroidal anti-inflammatory drugs (in particular, acetylsalicylic acid) and corticoids. Short-term use of non-steroidal anti-inflammatory drugs in the treatment of dysmenorrhoea does not appear to reduce contraceptive efficacy.

Insertion of an IUD is recommended during or shortly after menstruation. If a pregnancy can be excluded, the IUD may be inserted at any time during the cycle. Postpartum insertion should be postponed until six weeks after delivery, as earlier insertion is associated with high rates of perforation and expulsion. Using an IUD does not pose problems with breastfeeding.

The effect of an IUD is primarily triggered by the release of copper ions. They immobilize the sperm cells and thus prevent fertilization of the ovum. In addition, the copper ions alter the biochemical environment of the uterus and therefore inhibit implantation.